The Patent Finder

Endorecherche. Inc.

Also on record
Records under this name other than the patents Endorecherche. Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.

Back to Endorecherche. Inc.

PatentTitleStatus Expires Confidence
US 8,629,129Pharmaceutical Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,881,650Pharmaceutical Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,957,054Pharmaceutical Compositions
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 8,835,413Sex Steroid Precursors Alone or in Combination with a Selective Estrogen Receptor Modulator And/Or with Estrogens And/Or a Type 5 CGMP Phosphodiesterase Inhibitor for the Prevention and Treatment of Vaginal Dryness and Sexual Dysfunction in Postmenopausal Women
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,268,806Pharmaceutical Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,452,731A Method of Treating and Preventing Loss of Cognition
Lapsed on the fee record
Ended Sep 27, 2026 · High confidence
Lapsed on the fee recordEnded Sep 27, 2026High confidence
US 10,076,525Sex Steroid Precursors Alone or in Combination with Selective Estrogen Receptor Modulators for the Prevention and Treatment of Dyspareunia in Postmenopausal Women
Formerly held
Term ended
Term ended Oct 20, 2025 · High confidence
Term endedTerm ended Oct 20, 2025High confidence
US 10,478,443Sex Steroid Precursors Alone or in Combination with Selective Estrogen Receptor Modulators for the Prevention and Treatment of Sexual Dysfunction in Postmenopausal Women
Formerly held
Term ended
Term ended Oct 20, 2025 · High confidence
Term endedTerm ended Oct 20, 2025High confidence
US 9,744,177Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
Lapsed on the fee record
Ended Aug 29, 2025 · From the USPTO record
Lapsed on the fee recordEnded Aug 29, 2025From the USPTO record
US 9,682,960Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
Lapsed on the fee record
Ended Jun 20, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jun 20, 2025From the USPTO record
10 of 72 patents shown.
Pro members see all 72.
Pro members: see all 72 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited